Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma

INTRODUCTION: Dupilumab, a fully human anti-IL-4Rα monoclonal antibody, inhibits signaling of both interleukin (IL)-4 and IL-13, which are key drivers of type 2-mediated inflammation. Dupilumab is approved in the EU, USA, and other countries for the treatment of adults with inadequately controlled m...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Adv Ther
Main Authors: Busse, William W., Maspero, Jorge F., Rabe, Klaus F., Papi, Alberto, Wenzel, Sally E., Ford, Linda B., Pavord, Ian D., Zhang, Bingzhi, Staudinger, Heribert, Pirozzi, Gianluca, Amin, Nikhil, Akinlade, Bolanle, Eckert, Laurent, Chao, Jingdong, Graham, Neil M. H., Teper, Ariel
Formato: Artigo
Idioma:Inglês
Publicado: Springer Healthcare 2018
Assuntos:
Study Protocol
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5960488/
https://ncbi.nlm.nih.gov/pubmed/29725983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-018-0702-4
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares